Evaluating biomarkers in early autosomal dominant polycystic kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the value of NOX4 and other biomarkers related to mitochondrial injury and oxidative stress in determining disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD). It will involve a cross-sectional analysis of 60 patients aged 15 to 40 years, all classified as class 1 (A-E) based on imaging criteria and with an estimated glomerular filtration rate (eGFR) greater than 70 mL/min/1.73m2. The study will help identify real-time biomarkers that could provide insights into the progression of ADPKD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ADPKD (based on Ravine et al. criteria)
* Class 1 A-E according to imaging classification
* Male and female subjects 15 - 40 years of age
* Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI)
* Ability to provide written, informed consent

Exclusion Criteria:

* Class 2 according to imaging classification
* Concomitant systemic disease affecting the kidney
* Diabetes mellitus
* Predicted urine protein excretion in \>1 g/24 hrs
* Use of antioxidants i.e. vitamins, Nrf2 activators
* Abnormal urinalysis

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Maria V Irazabal, M.D., Ph.D. — Mayo Clinic

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Managing Depressive Symptoms in ADPKD: testing Digital Neurotherapy and Capacity Coaching

  This study tests whether Digital Neurotherapy or Capacity Coaching can help people with ADPKD who have depression and self-reported pain, compared to education alone.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07745920

• AZD1613 safety and how the body handles it in adults with ADPKD

  We will test whether AZD1613 given under the skin or into a vein is safe and how the body processes it in adults with ADPKD who have eGFR between 45 and 90 mL/min/1.73m2.

  Recruiting at 10 sites Phase 1 AstraZeneca · Birmingham, Alabama and 14 other locations · NCT07228364

• Intravenous ABBV-CLS-628 for adults with autosomal dominant polycystic kidney disease

  This trial will test whether intravenous ABBV-CLS-628 given every 4 weeks is safe and helps adults with ADPKD.

  Recruiting at 72 sites Phase 2 Calico Life Sciences LLC · Birmingham, Alabama and 90 other locations · NCT06902558

• National Registry for Rare Kidney Diseases

  This study is collecting health information from people with rare kidney diseases to help improve treatments and create better care guidelines.

  Recruiting UK Kidney Association · Bristol, South West · NCT06065852

• Using Metformin to Slow Kidney Decline in Polycystic Kidney Disease

  This study is testing if metformin can help slow down kidney problems in adults with early-stage Polycystic Kidney Disease.

  Recruiting at 24 sites Phase 3 The University of Queensland · Gosford, New South Wales and 48 other locations · NCT04939935

• Understanding oxidative stress in patients with Autosomal Dominant Polycystic Kidney Disease

  This study is testing how oxidative stress affects young adults with Autosomal Dominant Polycystic Kidney Disease to find better ways to treat the condition.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT04344769

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.